Several other chemotherapeutic agents, including cabazitaxel, sipuleucel-T, and alpharadin, as well as the Food and Drug Administration (FDA)-approved androgen synthesis inhibitors abiraterone acetate (new-generation antiandrogens) and enzalutamide (the novel androgen receptor (AR) inhibitor), are regularly prescribed for PC treatment, depending on patient conditions and the extent and location of the disease [7]. This evidence concerns the gene AR and pachyonychia congenita.